
Opinion|Videos|December 8, 2023
EMERALD Subgroup Analysis in Patients with Coexisting PIK3CA and TP53 Mutations
Author(s)Hope S. Rugo, MD
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
3
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
4
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
5































